New combo therapy targets early skin cancer: hope or hype?

NCT ID NCT06235281

Terminated Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether combining a targeted drug (mogamulizumab) with ultraviolet light therapy (phototherapy) can better control early-stage mycosis fungoides, a type of skin lymphoma. Twenty adults with stage IA-IIA disease will receive the drug for 8 cycles and add phototherapy from day 56. The main goal is to see how many patients achieve complete or partial clearing of skin lesions. The trial is currently on hold.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mogamulizumab (POTELIGEO) plus phototherapy (nb-UVB)
What this could lead to: If successful, this combination could offer a more effective way to control early-stage mycosis fungoides, potentially reducing skin lesions and delaying progression.
What could go wrong: This is a very early, small pilot study (20 people) with no comparison group. The trial is currently suspended, and results may not apply to all patients. Risks include side effects from the drug or phototherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYCOSIS FUNGOIDES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYCOSIS FUNGOIDES

Contacts and locations

Locations

Moffitt Cancer Center

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.